Life Science Investing Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Consistent Results after Dosing with EP-104GI 13 November
Life Science Investing Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results 04 November
Life Science Investing Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs 29 September
